StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
7
Publishing Date
2022 - 09 - 12
8
2022 - 03 - 15
10
2022 - 01 - 18
9
2022 - 01 - 05
9
2021 - 12 - 16
10
2021 - 12 - 14
10
2021 - 12 - 13
10
2021 - 12 - 10
7
2021 - 12 - 06
17
2021 - 12 - 01
9
2021 - 11 - 29
9
2021 - 11 - 15
10
2021 - 10 - 27
8
2021 - 10 - 13
7
2021 - 10 - 04
9
2021 - 09 - 29
8
2021 - 09 - 28
10
2021 - 09 - 27
7
2021 - 09 - 22
7
2021 - 09 - 20
7
2021 - 09 - 15
7
2021 - 09 - 13
13
2021 - 09 - 09
9
2021 - 09 - 08
7
2021 - 09 - 01
7
2021 - 07 - 22
7
2021 - 07 - 19
7
2021 - 07 - 06
7
2021 - 06 - 30
11
2021 - 06 - 29
8
2021 - 06 - 28
11
2021 - 06 - 24
8
2021 - 06 - 23
10
2021 - 06 - 22
7
2021 - 06 - 21
7
2021 - 06 - 16
10
2021 - 06 - 11
10
2021 - 06 - 10
7
2021 - 06 - 09
9
2021 - 06 - 08
11
2021 - 06 - 07
11
2021 - 06 - 04
7
2021 - 05 - 20
7
2021 - 05 - 12
7
2021 - 04 - 12
7
2021 - 04 - 06
8
2021 - 03 - 22
6
2021 - 03 - 16
7
2021 - 03 - 15
7
2021 - 02 - 25
8
2021 - 02 - 17
6
2021 - 02 - 04
7
2021 - 01 - 25
7
2021 - 01 - 11
6
2021 - 01 - 04
6
2020 - 12 - 21
6
2020 - 12 - 17
8
2020 - 12 - 15
10
2020 - 12 - 09
6
2020 - 12 - 07
8
Sector
Health technology
7
Tags
Acquisition
3
Application
6
Artificial intelligence
3
Awards
5
Biopharma
3
Biotech-beach
3
Brands
3
China
3
Clinical-trials-phase-ii
5
Collaboration
3
Commercialization
3
Communication
4
Communications
4
Conference
19
Contract
5
Covid
7
Device
5
Diagnostic
5
Diagnostics
3
Disease
5
Drug
5
Energy
11
Enroll
3
Europe
3
Events
4
Fda
3
Financial results
4
Genetown
3
Growth
11
Health
11
License
3
Life science
5
Liver
10
Market
3
Media
5
Money
4
N/a
265
Offering
12
Partnership
7
People
5
Pharm-country
3
Phase 2
7
Phase 3
4
Positive
5
Potential
3
Pre-clinical
4
Preclinical
4
Presentation
7
Program
4
Publication
4
Report
3
Research
19
Response
5
Results
12
Technology
9
Test
6
Therapy
4
Treatment
13
Trial
13
Women
4
Entities
Aligos therapeutics, inc.
1
Anavex life sciences corp.
1
Innoviva, inc.
1
Medicinova, inc.
1
Oyster point pharma, inc.
1
Redhill biopharma ltd.
1
Spruce biosciences, inc.
1
Theravance biopharma, inc.
1
Symbols
ALGS
1
AVXL
1
INVA
1
MNOV
1
OYST
1
RDHL
1
SPRB
1
TBPH
1
Exchanges
Nasdaq
7
Crawled Date
2021 - 06 - 21
7
Crawled Time
11:00
2
12:00
3
13:00
1
14:00
1
Source
www.biospace.com
6
www.globenewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
publishing date :
2021 - 06 - 21
tags :
Phase 2
save search
Aligos Therapeutics to Present Phase 1 Safety and Pharmacokinetic Data for STOPS™ Molecule Drug Candidate ALG-010133
Published:
2021-06-21
(Crawled : 14:00)
- biospace.com/
ALGS
|
$0.808
-3.23%
-3.34%
120K
|
Health Technology
|
-96.77%
|
O:
0.04%
H:
5.75%
C:
4.02%
phase 1
drug
phase 2
phase 3
Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism
Published:
2021-06-21
(Crawled : 13:00)
- biospace.com/
SPRB
|
$0.7047
0.64%
0.64%
690K
|
Health Technology
|
-93.94%
|
O:
-0.26%
H:
0.17%
C:
-12.15%
phase 2
phase 2 results
results
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Biomarker Correlated with Efficacy Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome
Published:
2021-06-21
(Crawled : 12:00)
- biospace.com/
AVXL
|
$4.065
-1.34%
-1.35%
1.3M
|
Health Technology
|
-81.39%
|
O:
8.67%
H:
15.75%
C:
4.61%
treatment
phase 2
life science
trial
anavex®2-73
anavex
syndros
biomarkers
rett syndrome
Oyster Point Pharma Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial of OC-01 (varenicline) Nasal Spray for Patients with Neurotrophic Keratopathy
Published:
2021-06-21
(Crawled : 12:00)
- biospace.com/
OYST
|
$11.17
0.18%
-0.27%
|
Health Technology
|
-44.69%
|
O:
0.99%
H:
3.19%
C:
-4.08%
nasal spray
phase 2
trial
enroll
RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19
Published:
2021-06-21
(Crawled : 12:00)
- biospace.com/
RDHL
|
$0.3935
2.21%
2.16%
240K
|
Health Technology
|
-94.48%
|
O:
0.43%
H:
1.57%
C:
-1.14%
covid
presentation
phase 2
biopharma
positive
opaganib
covid-19
Theravance Biopharma, Inc. Announces Top-Line Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19
Published:
2021-06-21
(Crawled : 11:00)
- biospace.com/
TBPH
|
$9.535
-1.6%
-1.63%
310K
|
Health Technology
|
-44.69%
|
O:
-4.11%
H:
5.71%
C:
4.52%
INVA
|
$14.48
0.07%
0.07%
520K
|
Health Technology
|
8.55%
|
O:
0.53%
H:
0.37%
C:
0.15%
covid
phase 2
biopharma
results
topline
MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal
Published:
2021-06-21
(Crawled : 11:00)
- globenewswire.com
MNOV
|
$1.43
-5.92%
-6.29%
40K
|
Health Technology
|
-59.57%
|
O:
33.24%
H:
1.6%
C:
-16.17%
alcohol use disorder
phase 2
positive results
positive
results
trial
mn-166
Gainers vs Losers
57%
43%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
1.9M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
800K
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.